Radioactive Iodine (I-131): Uses, Safety, and What to Expect

What Is Radioactive Iodine and How Does It Work?

Radioactive iodine (sodium iodide I-131) is a beta and gamma emitter that the thyroid gland absorbs almost exclusively through the same sodium-iodide symporter it uses to process dietary iodine. Once inside follicular cells, the beta radiation travels only about 2 millimeters, destroying the tissue that absorbed it while sparing the parathyroid glands, recurrent laryngeal nerves, and surrounding neck structures. That tissue specificity is why I-131 has been a standard of care for thyroid disease since the 1940s.

The physical half-life of I-131 is 8.02 days. Most of the radiation dose is delivered within 30 to 60 days. Residual whole-body exposure is low enough that the U.S. Nuclear Regulatory Commission generally allows outpatient administration for doses below 33 mCi, though individual state regulations vary and your treating center will set the specific threshold. [1]

The American Thyroid Association's 2016 guidelines confirm that I-131 remains one of three accepted first-line options for Graves disease alongside antithyroid drugs and thyroidectomy, and that choice should be individualized. [2]

Who Is a Candidate for I-131?

Not every patient with hyperthyroidism or thyroid cancer is the right candidate. Absolute contraindications include confirmed or possible pregnancy and active breastfeeding, because I-131 crosses the placenta and concentrates in fetal thyroid tissue, and is secreted in breast milk at levels that can ablate an infant's thyroid. [2]

Relative contraindications include moderate-to-severe active Graves ophthalmopathy, because RAI therapy may transiently worsen orbitopathy in some patients. A 2015 Cochrane review found that glucocorticoid co-administration during RAI reduces this risk significantly in patients with pre-existing eye disease. [3] Women of childbearing age should avoid conception for at least 6 months after I-131 treatment; many centers recommend 12 months following high-dose therapy for thyroid cancer.

Good candidates for I-131 include:

• Adults with Graves disease who have failed or cannot tolerate methimazole
• Patients with toxic multinodular goiter or a solitary toxic adenoma
• Post-surgical patients with differentiated thyroid cancer (papillary or follicular) with residual tissue or known metastatic disease

Patients with large goiters causing compressive symptoms are often better served by surgery, because RAI does not reliably reduce gland volume quickly enough to relieve tracheal compromise.

Dosing: Hyperthyroidism vs. Thyroid Cancer Ablation

The dose strategy differs substantially between the two indications.

Hyperthyroidism: Fixed-dose protocols typically use 10 to 15 mCi for Graves disease. Calculated-dose protocols use 24-hour radioactive iodine uptake (RAIU) testing to tailor the dose to gland size and uptake fraction, with the goal of delivering 80 to 200 Gray to the gland. Both approaches produce comparable rates of euthyroidism or hypothyroidism, though the calculated method may modestly reduce the probability of a second treatment. [2]

Thyroid cancer: Post-surgical remnant ablation doses typically range from 30 to 100 mCi for low-risk differentiated thyroid cancer. High-risk disease or distant metastases may require 100 to 200 mCi. The 2015 American Thyroid Association thyroid cancer guidelines stratified patients into low, intermediate, and high recurrence-risk groups, with RAI recommended only when the expected benefit outweighs the small but real risks of salivary gland damage, lacrimal gland dysfunction, and secondary malignancy at cumulative high doses. [4]

Recombinant human TSH (rhTSH, brand name Thyrogen) can be used to stimulate iodine uptake before RAI without requiring thyroid hormone withdrawal, preserving quality of life. A phase III trial (N=63) published in the Journal of Clinical Endocrinology and Metabolism confirmed that rhTSH-aided ablation is non-inferior to thyroid hormone withdrawal for successful ablation at 8-month follow-up (success rate 77% vs. 79%). [5]

Preparing for I-131: The Low-Iodine Diet and Drug Holds

The low-iodine diet reduces thyroid iodine stores so that follicular cells are maximally "hungry" for I-131. Patients follow the diet for 1 to 2 weeks before treatment. Key restrictions include iodized salt, seafood, dairy products, egg yolks, red food dyes (FD&C Red No. 3 contains iodine), and processed breads that use iodate dough conditioners.

Several medications must be held before treatment. Methimazole and propylthiouracil (PTU) blunt iodine uptake when taken within 5 to 7 days of RAI. Amiodarone, a heavily iodinated antiarrhythmic, can suppress uptake for 6 to 12 months after the last dose and requires coordinated planning between cardiology and endocrinology before proceeding. Levothyroxine or liothyronine must be stopped for 4 to 6 weeks (for T4) or 2 weeks (for T3) before thyroid cancer ablation done via thyroid hormone withdrawal rather than rhTSH. [4]

Beta-blockers such as propranolol may be continued through RAI to control symptomatic hyperthyroidism and are typically tapered once thyroid function normalizes over the following weeks.

What to Expect on Treatment Day and During Isolation

I-131 is swallowed as a clear, tasteless liquid or a gelatin capsule. The entire process at the nuclear medicine or endocrinology suite takes 30 to 60 minutes. Most patients feel nothing immediately. Mild neck soreness or tenderness may develop within 7 to 10 days as thyroid tissue swells and then begins to involute.

Post-treatment isolation instructions protect family members, coworkers, and especially children and pregnant women from incidental radiation exposure. The NRC-recommended general guidance includes: [1]

• Sleep at least 6 feet from a partner for 5 to 7 days
• Avoid prolonged close contact with children (under 18) and pregnant women for 5 to 7 days
• Use separate utensils and flush the toilet twice for the first 2 days
• Return to work varies by job type: an office worker may return in 3 to 5 days, while a schoolteacher working with young children may need 7 to 10 days

Salivary gland inflammation (sialadenitis) occurs in up to 30% of patients receiving doses above 100 mCi. Sucking on hard candy (particularly sour lemon candies) starting 24 hours after RAI stimulates salivary flow and may reduce this complication. Evidence from a 2008 study in the Archives of Otolaryngology supports starting lemon candies at 24 hours rather than immediately after dosing, since early stimulation might theoretically increase I-131 retention in salivary tissue. [6]

Hypothyroidism After I-131: The Most Common Long-Term Outcome

This is the outcome most patients underestimate. For Graves disease treated with an ablative I-131 dose, roughly 80% of patients are hypothyroid by 12 months and nearly all are hypothyroid by 5 years. [2] Patients should be tested with TSH and free T4 at 4 to 6 weeks after treatment, then every 4 to 8 weeks until stable, and annually thereafter.

Thyroid hormone replacement is the standard long-term treatment. The choice among available agents depends on individual patient biochemistry, tolerability, and physician preference.

Levothyroxine (Synthroid, Tirosint, Generic T4)

Levothyroxine is the first-line replacement for post-RAI hypothyroidism per ATA and American Association of Clinical Endocrinologists guidelines. [7] It supplies synthetic T4, which peripheral tissues convert to the active T3 hormone via deiodinase enzymes. The average replacement dose is 1.6 mcg/kg/day, titrated to a TSH of 0.5 to 2.5 mIU/L for most patients without a cancer history.

Standard levothyroxine tablets (generic, Synthroid) contain inactive fillers including lactose and acacia. Tirosint is a gel-cap formulation of levothyroxine in glycerin and gelatin with no dyes, acacia, lactose, or gluten. A 2017 study (N=84) in Thyroid found that patients with gastrointestinal disorders and absorption problems achieved significantly better TSH stability on Tirosint than on standard tablets, with 63% reaching target TSH on the liquid formulation vs. 39% on tablets (P<0.05). [8] Tirosint-SOL, the liquid-drop form, offers the same inert-excipient benefit and can be useful for patients with swallowing difficulties or those requiring very precise pediatric dosing.

Levothyroxine must be taken 30 to 60 minutes before food on an empty stomach. Calcium carbonate, iron supplements, proton pump inhibitors, and cholestyramine each reduce absorption by 20 to 40% when taken simultaneously. [9]

Liothyronine (Cytomel, Generic T3)

Liothyronine is synthetic T3, the biologically active thyroid hormone that binds directly to nuclear receptors. Its oral bioavailability is close to 95% and its half-life is approximately 1 day, compared with 7 days for levothyroxine.

A randomized trial published in the New England Journal of Medicine (NEJM 1999, N=33) reported that patients on a combination of levothyroxine plus liothyronine showed improved mood and neuropsychological function compared with T4 monotherapy. [10] The evidence since has been mixed: a Cochrane systematic review of 14 trials (N=1,216) concluded that combination T4 plus T3 therapy did not consistently outperform T4 monotherapy on quality-of-life measures when the overall population was analyzed, though a subset of patients with the type 2 deiodinase Thr92Ala polymorphism may respond better to combination therapy. [11]

Liothyronine is sometimes prescribed for post-RAI patients who report persistent fatigue, brain fog, or depression despite a normal TSH on levothyroxine alone. A typical starting add-on dose is 5 mcg once or twice daily, reducing the levothyroxine dose by 25 mcg for each 5 to 10 mcg of liothyronine added.

Natural Desiccated Thyroid (Armour Thyroid, NP Thyroid, WP Thyroid)

Natural desiccated thyroid (NDT) is derived from porcine (pig) thyroid glands and contains both T4 and T3 in a fixed ratio of approximately 4:1 by weight, corresponding to about 38 mcg T4 and 9 mcg T3 per 60 mg (one grain) tablet. This T4:T3 ratio is lower than the typical human thyroid's secretion ratio of roughly 14:1, meaning NDT delivers a relatively higher T3 load than most patients' thyroids would naturally produce. [12]

Armour Thyroid is the most widely dispensed brand. NP Thyroid (Acella) and WP Thyroid (RLC Labs) are alternatives, though WP Thyroid has experienced supply disruptions. A 2013 randomized crossover trial (N=70) published in the Journal of Clinical Endocrinology and Metabolism found that 48.6% of patients preferred desiccated thyroid extract to levothyroxine, 18.6% preferred levothyroxine, and 32.9% had no preference. Patients on NDT lost an average of 2.2 lb more during the study period. [13]

The higher T3 content in NDT can cause transient palpitations, anxiety, or flushing in some patients, particularly in the first few hours after dosing. Splitting the daily dose (morning and mid-afternoon) helps blunt peak T3 levels. NDT is not recommended as first-line therapy by most major guidelines, but it is a reasonable alternative for patients who have done poorly on levothyroxine alone, provided TSH and free T3 are monitored closely. [7]

TSH Suppression for Thyroid Cancer Patients

Patients treated with I-131 for differentiated thyroid cancer have a different TSH target than those treated for benign hyperthyroidism. TSH stimulates any residual thyroid cancer cells through the TSH receptor, so intentional TSH suppression with higher levothyroxine doses reduces recurrence risk.

The 2015 ATA thyroid cancer guidelines recommend: [4]

• High-risk disease: TSH below 0.1 mIU/L indefinitely, provided cardiovascular and bone risks are acceptable
• Intermediate-risk disease: TSH 0.1 to 0.5 mIU/L for 5 to 10 years
• Low-risk, excellent response: TSH can be normalized to 0.5 to 2.0 mIU/L

Suppressive therapy carries real trade-offs. A meta-analysis of 12 studies published in the Journal of Bone and Mineral Research found that TSH-suppressive levothyroxine therapy was associated with a 1 to 2% per year reduction in hip bone mineral density in postmenopausal women. [14] Atrial fibrillation risk also rises with sustained subclinical hyperthyroidism (TSH below 0.1 mIU/L), as documented in the Rotterdam Study cohort (N=1,426). [15] Annual bone density screening and cardiac monitoring are standard for patients on prolonged suppressive therapy.

Monitoring After I-131: A Practical Schedule

Post-RAI follow-up should not be sporadic. A workable monitoring schedule includes:

• 4 to 6 weeks post-treatment: TSH, free T4 (start levothyroxine if TSH above 10 mIU/L or symptomatic)
• Every 6 to 8 weeks: Repeat TSH, free T4 until two consecutive values within target range
• Every 6 to 12 months (stable): TSH, free T4, and free T3 if on combination therapy or NDT
• Thyroid cancer patients: Annual thyroglobulin (Tg) and anti-Tg antibodies, neck ultrasound every 6 to 12 months for 5 years, then as risk dictates [4]

Persistent elevation of thyroglobulin after I-131 ablation, especially a rising trend, warrants repeat whole-body scan or additional imaging. Anti-thyroglobulin antibodies can falsely lower immunometric Tg assays; their presence should prompt reflex Tg measurement by mass spectrometry.

Drug Interactions and Absorption Pitfalls

The most common reason a patient on post-RAI levothyroxine has an unexpectedly elevated TSH is an absorption interaction, not a wrong dose. A brief list of the most clinically significant interactions:

• Calcium carbonate: Reduces T4 absorption by up to 40% if taken within 4 hours. [9]
• Ferrous sulfate: Similar magnitude of interference; iron supplements should be separated by at least 2 to 4 hours.
• Proton pump inhibitors (omeprazole, pantoprazole): Increase gastric pH and reduce T4 dissolution; Tirosint or Tirosint-SOL may absorb more reliably in achlorhydric patients. [8]
• Cholestyramine and colestipol: Bind T4 in the gut; separate by 4 to 6 hours.
• High-fiber diets and soy protein: Modestly reduce absorption; advise consistent dietary patterns rather than elimination.
• Estrogens: Increase thyroid-binding globulin, raising total T4 but usually not free T4; oral contraceptive or HRT initiation may require a small levothyroxine dose increase.
• Amiodarone: Inhibits T4-to-T3 conversion and TSH secretion; thyroid function monitoring every 3 to 6 months is advised in any patient on both drugs.

Reproductive Considerations and Pregnancy

Women of reproductive age who receive I-131 should avoid pregnancy for at least 6 months after ablative doses for hyperthyroidism and at least 12 months after high-dose therapy for thyroid cancer. This waiting period allows radiation clearance, thyroid function stabilization, and optimal levothyroxine dosing before conception.

Pregnancy substantially increases the levothyroxine requirement. Thyroid hormone needs rise by 25 to 50% by 7 to 8 weeks gestation due to rising hCG levels, increased thyroid-binding globulin from estrogen, and placental type 3 deiodinase activity. The Endocrine Society's 2012 clinical practice guideline on thyroid and pregnancy recommends increasing levothyroxine by two additional doses per week (about a 30% increase) at the time of a positive pregnancy test for women with known hypothyroidism, pending formal TSH testing. [16] TSH targets during pregnancy are trimester-specific: below 2.5 mIU/L in the first trimester and below 3.0 mIU/L in the second and third trimesters. [16]